Scaling down successful programs or transitioning from morbidity control to transmission control introduces challenges that are both technical and social, particularly in terms of the expectations of communities and health workers.
Responsible exit strategies need to be developed to address public health impacts (e.g., the effect of withdrawing ivermectin and albendazole for lymphatic filariasis on soil-transmitted helminths, strongyloidiasis, and scabies) as well as other social impacts, including how best to capitalize on the enormous investment in developing the large cadre of community drug distributors over the many years of MDA-based programs.
Key research projects include:
Developing strategies for monitoring for drug resistance
Click here for a map of where the research projects are being implemented: http://www.ntdsupport.org/projects